Related Experiment Videos

The effect of naftidrofuryl ('Praxilene') on hepatic microsomal enzymes

Pharmatherapeutica
|January 1, 1980
PubMed

Insights

Naftidrofuryl did not significantly alter serum gamma-glutamyl transpeptidase (GGT) levels in male patients. This suggests naftidrofuryl does not induce hepatic microsomal enzymes, minimizing drug interaction concerns.

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Trials

Background:

  • Gamma-glutamyl transpeptidase (GGT) is a marker for hepatic microsomal enzyme induction.
  • Assessing drug effects on liver enzymes is crucial for predicting drug metabolism and interactions.

Purpose of the Study:

  • To evaluate the impact of naftidrofuryl on serum GGT levels.
  • To determine if naftidrofuryl induces hepatic microsomal enzymes.

Main Methods:

  • A double-blind, placebo-controlled trial.
  • 32 male patients received naftidrofuryl (40 mg i.m. 3-times daily for 6 days) or placebo.
  • Serum GGT levels were measured before and after treatment.

Main Results:

  • No significant difference in serum GGT levels was observed between the naftidrofuryl and placebo groups.
  • Mean post-treatment GGT levels in the naftidrofuryl group were lower than pre-treatment levels.
  • Naftidrofuryl did not elevate serum GGT, indicating no significant enzyme induction.

Conclusions:

  • Naftidrofuryl does not appear to induce hepatic microsomal enzymes.
  • Concerns regarding naftidrofuryl interfering with the metabolism of concurrently used drugs via enzyme induction are likely unfounded.

Related Concept Videos